Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Jan / Small But Mighty… Molecular Pathology
Oncology Biochemistry and molecular biology Genetics and epigenetics Oncology Molecular Pathology

Small But Mighty… Molecular Pathology

Although it specializes in the very small, the field of molecular pathology is taking giant steps in research

By George Francis Lee 01/11/2023 News 1 min read

Share

By our powers combined…
 

A newly created framework – “sc-linker” – combines single-cell RNA sequencing, epigenomic SNP-to-gene maps, and genome-wide association study (GWAS) statistics to identify the cell types and cellular processes genetic variants use to influence disease. The team detected subtle differences in SNP-to-gene mapping between tissues, with strong differences in disease heritability across cell types (1).

Two-faced collagen
 

Type I collagen remodeling is associated with differing outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). Matrix-metalloproteinase-cleaved type I collagen activates discoidin domain receptor 1 (DDR1), signaling tumor growth; the intact protein triggers DDR1 degradation and hinders tumor growth (2).

Clear-headed hepatic health
 

Analysis of 9,491 cases combined with proton density fat fraction from 36,116 liver images has revealed 18 sequence variants associated with non-alcoholic fatty liver disease (3). Four variants linked with cirrhosis were found. Loss-of-function variants were found in MTARC1 and GPAM, indicating they may have potential as future drug targets.

Something to ASPYRE to
 

A highly sensitive model to detect gene fusions, called ASPYRE, shows rapid and consistent results even with low sample sizes. The method eliminates multiple instrument runs and uses pyrophosphorolysis to detect gene fusions from RNA and DNA simultaneously. The workflow and equipment are similar to standard PCR assays, with turnaround times under 24 hours (4).

Testing for treatment
 

The antibody-drug conjugate enfortumab vedotin has been approved to treat metastatic urothelial carcinoma (mUC). However, recent research reveals that expression of the treatment’s target – NECTIN-4 – is frequently decreased in mUC and 39.4 percent of metastases exhibit no membranous NECTIN-4 expression at all. The authors strongly recommend determining NECTIN-4 status prior to selecting treatment for mUC (5).

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

    1. KA Jagadeesh, et al., “Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics,” Nat Genet, 54, 1479 (2022). PMID: 36175791.
    2.  H Su et al., “Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome,” Nature, 610, 366 (2022). PMID: 36198801.
    3. G Sveinbjornsson, et al., “Multiomics study of nonalcoholic fatty liver disease,” Nat Genet, 54, 1652 (2022). PMID: 36280732.
    4. ER Gray, et al., “Ultra-sensitive molecular detection of gene fusions from RNA using ASPYRE,” BMC Med Genomics, 15, 215 (2022). PMID: 36224552.
    5. N Klümper et al., “Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance,” Clin Cancer Res, [Online ahead of print] (2022). PMID: 36534531.

About the Author(s)

George Francis Lee

Interested in how disease interacts with our world. Writing stories covering subjects like politics, society, and climate change.

More Articles by George Francis Lee

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Biochemistry and molecular biology
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

Molecular Spectacular
Biochemistry and molecular biology
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

qPCR Infectious Disease Detective
Biochemistry and molecular biology
qPCR: Infectious Disease Detective

January 4, 2024

3 min read

How quantitative polymerase chain reaction really hits the mark in epidemic control and ID detection

Case of the Month
Biochemistry and molecular biology
Case of the Month

January 11, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.